Navigation Links
Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma.

                           Conference Call Numbers

                              Wednesday, July 11

       1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European

                       1-800-240-7305 (US Participants)

                        1-303-262-2137 (International)


                            Live audio webcast at

                             www.cticseattle.com

                     will be archived for post listening

       approximately two hours after call ends, available for five days


     Call-back numbers for post listening available at 6:30 p.m. Eastern:

                       1-800-405-2236 (US Participants)

                        1-303-590-3000 (International)

                             Passcode: 11093505#


     Media Contact:


     Cell Therapeutics, Inc.

     Dan Eramian

     T: 206.272.4343

     C: 206.854.1200

     Susan Callahan

     T: 206.272.4472

     F: 206.272.4434

     E: 

     www.cticseattle.com/media.htm


     Investors Contact:


     Cell Therapeutics, Inc.

     Leah Grant

     T: 206.282.7100

     F: 206.272.4434

     E: 

     www.cticseattle.com/investors.htm

media@ctiseattle.com invest@ctiseattle.com

CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com

Web site: http://www.cticseattle.com//

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
2. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
3. Choosing Lab Quality Management Software
4. Optimizing Quality Control Data Management
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
11. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):